Link: https://medicalinformation.astrazeneca-us.com/home/prescribing-information/imfinzi.html
Description: WEBIMFINZI® (durvalumab) durvalumab. Jump To Highlights of Prescribing Information SPL product data elements section. RECENT MAJOR CHANGES SECTION. 1 INDICATIONS AND USAGE. 2 DOSAGE AND ADMINISTRATION. 3 DOSAGE FORMS AND STRENGTHS. 4 CONTRAINDICATIONS. 5 WARNINGS AND PRECAUTIONS. 6 …
DA: 74 PA: 20 MOZ Rank: 87
Link: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761069s018lbl.pdf
Description: WEBIMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who: have disease...
DA: 85 PA: 41 MOZ Rank: 21
Link: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761069s029lbl.pdf
Description: WEBIMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: for the treatment of adult patients with unresectable, Stage III non-small cell lung cancer (NSCLC) whose disease has...
DA: 11 PA: 12 MOZ Rank: 98
Link: https://ce.mayo.edu/sites/default/files/IMFINZI%C2%AE%20%28durvalumab%29%20US%20Prescribing%20Information.pdf
Description: WEBIMFINZI is indicated for the treatment of adult patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
DA: 10 PA: 41 MOZ Rank: 78
Link: https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/9496217c-08b3-432b-ab4f-538d795820bd/9496217c-08b3-432b-ab4f-538d795820bd_viewable_rendition__v.pdf
Description: WEBHIGHLIGHTS OF PRESCRIBING INFORMATION. These highlights do not include all the information needed to use IMFINZI safely and effectively. See full prescribing information for IMFINZI. IMFINZI® (durvalumab) injection, …
DA: 81 PA: 81 MOZ Rank: 46
Link: https://www.imfinzihcp.com/metastatic-nsclc/dosing.html
Description: WEBRecommended Dosage. The POSEIDON Regimen: Finite anti–CTLA-4 dosing with dual IO + platinum-based CT 1,2. RECOMMENDED DOSAGE FOR PATIENTS WITH BODY WEIGHT ≥30 KG1-3. For patients with body weight <30 kg1,2. Cycles 1-4 (Q3W): Platinum-based CT* IMJUDO 1 mg/kg. IMFINZI 20 mg/kg. Cycles 5 and later (Q4W):
DA: 1 PA: 82 MOZ Rank: 6
Link: https://www.fda.gov/drugs/resources-information-approved-drugs/durvalumab-imfinzi
Description: WEBFull prescribing information is available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761069s000lbl.pdf. The FDA granted this application accelerated approval, priority...
DA: 52 PA: 36 MOZ Rank: 49
Link: https://www.astrazeneca.com/content/dam/az-ca/downloads/productinformation/imfinzi-product-monograph-en.pdf
Description: WEBAdminister Imfinzi prior to chemotherapy when given on the same day. Please also refer to the full prescribing information for etoposide, carboplatin or cisplatin, in their respective Product Monographs. Locally Advanced or Metastatic Biliary Tract Cancer The recommended dose of Imfinzi is 1500 mg in combination with gemcitabine-based
DA: 24 PA: 73 MOZ Rank: 46
Link: https://www.imfinzi.com/
Description: WEBIMFINZI may be used in combination with IMJUDO and chemotherapy that contains platinum when your NSCLC has spread to other parts of your body (metastatic) and your tumor does not have an abnormal “EGFR” or “ALK” gene. IMFINZI is used to treat adults with a type of lung cancer called SCLC.
DA: 35 PA: 63 MOZ Rank: 51
Link: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761069s020lbl.pdf
Description: WEBFULL PRESCRIBING INFORMATION . 1 INDICATIONS AND USAGE . 1.1 Urothelial Carcinoma IMFINZI is indicated for the treatment of adult patients with locally advanced or metastatic urothelial...
DA: 74 PA: 35 MOZ Rank: 6
